Exhibit 99.1 Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 - - Webcast Conference Call Scheduled Today at 8:00 a.m. ET - Purchase, NY – March 26, 2024 – Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company de ...